110 results about "Biopharmacology" patented technology

The method of reducing pain in a patient by combining a traditional pharmacological treatment with electro-acupuncture or percutaneous electrical nerve stimulation therapy. The pharmacological treatment consists of using analgesics such as morphine sulfate and hydromorphine provided to patients around the clock or as needed for pain. The patient controlled analgesia pump (PCA) is used by patients for self-administering of analgesia as needed. After patient stops using PCA pump narcotic and non-narcotic pain medications are administered mostly orally. Typically, there are two pairs of needle electrodes, two on each leg, connected to two separate outputs of the portable electrical stimulator. The constructions of the needle holder and the stimulator allow a patient to move freely and, if necessary, to carry the device during the entire day.

The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to hypertension, especially in medical interventions involving dilatation and remodeling of arterial blood vessels, either in the pulmonary or in the systemic circulation. The peptides which can be used according to the invention for the treatment of said diseases comprise at least one specific highly conservative amino acid residue sequence which seem to play an important role in connection with pulmonary and arteriolar hypertension events. It could be shown that the known naturally occurring peptides “vasoactive intestinal peptide (VIP)” and “pituitary adenylate cyclase-activating polypeptide (PACAP)”, having these specific sequences are potent drugs which can be successfully used for treatment of primary pulmonary hypertension (PPH), secondary pulmonary hypertension (SPH), and hypertension of the systemic circulation. Furthermore, the present invention discloses pharmaceutical compositions useful for treatment of PPH, SPH, and hypertension of the systemic circulation within said methods.

The invention discloses an in-vitro individualized medicine test method for lung cancer and a culture medium, and belongs to the field of cell biology and pharmacology. The in-vitro individualized medicine test method and the culture medium have the advantages that the culture medium M can be applied to normal epithelial cells and primary tumor cells of human or mammals, accordingly, in-vitro culture systems for tumor cells and para-carcinoma cells of lung cancer patients can be established, and primary cells, with continuous passage and quick proliferation functions, of patient individuals can be obtained; the culture systems can be used for detecting the sensitivity and the safety of medicines or combination groups of the medicines, and accordingly stable, accurate and reliable lung cancer individualized treatment-medicine sensitivity test standard detection process systems can be established; individualized sensitive chemotherapy medicines or compositions screened by the aid of the lung cancer individualized treatment-medicine sensitivity test standard detection process systems can be combined with clinical medicine or relevant subjects, accordingly, clinical individualized treatment schemes can be formulated, and the in-vitro individualized medicine test method and the culture medium can ultimately serve for clinical application.

The invention belongs to the technical field of traditional Chinese health care products and at least relates to a health care product formula of dendrobium officinale. The formula is provided for mainly solving the problem that the production cost of a health care product is reduced on the premise of ensuring that the immunity health care effect is at least enhanced. The components in the formula comprise monarch drugs, a ministerial drug and an adjuvant drug, wherein the monarch drugs comprise fresh dendrobium officinal and cordyceps sinensis powder; American ginseng is used as the ministerial drug; and medlar is used as the adjuvant drug. The formula at least has the efficacy for enhancing the immunity in the traditional Chinese medicine or pharmacology aspect; and meanwhile, the production cost of the health care products can be greatly reduced.

Stabilizing catheters for delivery of one or more protein drugs to a patient. The stabilizing catheter embodiments of the invention maintain or preserve a biologically / pharmacologically active form of the protein drug for delivery to a site within the body. Particular embodiments include a tubing layered with a hydrophilic and mobile polymer that aids in the maintenance or preservation of an active conformer of the protein drug. These embodiments of the stabilizing catheter prevent site loss of protein drugs, such as insulin. Other embodiments include a tubing that is layered with a material that substantially prevents diffusion of small, insulin formulation-stabilizing molecules out from the catheter, as well as substantially prevents the diffusion of small, insulin formulation-destabilizing molecules into the catheter, during a period of insulin infusion. In effect, these embodiments of the stabilizing catheter maintain the stabilizing effect of a particular insulin formulation, and consequently, substantially prevents occlusions / deposits from being formed during a period set for insulin delivery. Still other embodiments are directed to a combination of these features of the stabilizing catheters of the invention.

The present invention relates to isolated liver progenitor stem cells, and cell population thereof, wherein said progenitor stem cells originate from adult liver, esp. of human. The present invention also relates to the use of said isolated progenitor stem cells in medicine, hepatology, inborn errors of liver metabolism, transplantation, infectious diseases, liver failure. The present invention also relates to methods of isolating these cells, their culture, characterization before and after differentiation, and their use for transplantation, animal models of human disease, toxicology and pharmacology.

Provided herein are compositions and methods for treating a subject suffering from Fragile X syndrome, autism, Down's syndrome, mental retardation, or a neuropsychiatric condition (e.g., schizophrenia). The methods include systemic administration of a a therapeutically effective amount of a PAK inhibitor in combination with a Group I mGluR antagonist (e.g., an mGluR5 antagonist). The PAK inhibitor and mGluR antagonist can be administered together, e.g., in one pharmacological composition, or they can be administered separately.

The invention relates to a common anemarrhena polysaccharide extractive with immunosuppression activity and a preparation method and medicine purposes thereof. The preparation method comprising the steps of degreasing raw materials, extracting the degreased raw materials with water, precipitating the extracted material with alcohol, carrying out dialysis and ion-exchange column chromatography on the crude polysaccharide to eliminate proteins, pigments and molecular chemical components to produce an anemarrhena extractive. A huge amount of pharmacological experiments prove that common anemarrhena polysaccharide has an immunodepression activity and has the medical purposes of treating proinflammatory traumatic diseases, such as nephritis, pneumonia, upper respiratory tract infection, hepatitis, tonsillitis and diabetes.

The present invention relates (a) to new compounds represented by Formula I: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, D represents a nonsteroidal subunit (nonsteroidal moiety) derived from nonsteroid drug with anti-inflammatory, analgesic and / or antipyretic activity (NSAID) and L represents a linking group covalently linking M and D; (b) to their pharmacologically acceptable salts, prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory diseases and conditions in humans and animals.

The invention provides a preparation method of a conjugate in the formula (I) and application thereof as medicine preventing or treating liver cirrhosis, adiposis hepatica, hyperlipidemia, hyperglycemia, obesity and hepatic fibrosis. Pharmacological experiments find that the conjugate has drug activity with various value. Specifically, the conjugate shows the functions of reducing blood sugar and low-density lipoprotein and improving the transaminase level in animal experiments. Besides, the invention further relates to a preparation, a preparation method and application of the conjugate.

The invention relates to a preparation method of an immunosuppressive activity plantago seed extractive and applications thereof. The preparation method comprises the following steps of: degreasing raw materials and obtaining crude extractive through water extraction and alcohol precipitation; deproteinizing and depigmenting the crude extractie through dialysis and ion exchange chromatography; and removing micromolecular chemical compositions to prepare the plantago seed extractive with higher purity. A total polysaccharide content in the inventive immunosuppressive activity plantago seed extractive accounts more than 72% of the extractive by weight. Shown by a great amount of pharmacological experiments, the plantago seed extractive has immunosuppressive activity, can be used for preparing immune inhibitors in various preparation forms or used as a raw material medicine for preparing other immunosuppressive medicines and used for medical purposes in treating diseases related to immune inflammatory injuries, such as nephritis, cystitis, prostatitis, urethritis, edema and eye diseases, such as uveitis, interstitial keratitis, corneal transplantation rejection, and the like.

The invention discloses a Guangxi rubus suavissimus antidiabetic potential marker metabolic pathway based on the metabonomics and a research method, which relates to a research method for a natural plant medicine action mechanism. The invention aims at solving the problems that the existing single pharmacology method cannot systematically and comprehensively evaluate the action mechanism of the natural plant medicine. The method comprises the following steps: (1) detecting and analyzing a urine metabolite of a diabetic rat after being induced by streptozotocin and intervened by rubus suavissimus; (2) selecting nine rubus suavissimus antidiabetic related urine potential markers, and identifying the potential markers; and (3) selecting six metabolic pathways of the rubus suavissimus for resisting the diabetics, and analyzing. By adopting the Guangxi rubus suavissimus antidiabetic potential marker metabolic pathway and the research method, the antidiabetic action mechanism of the rubus suavissimus can be more comprehensively, efficiently, rapidly and integrally evaluated without deviation, and evidence can be provided for the description and further development of the national medicine action mechanism.

The present invention relates to pharmacology bioassays used in drug discovery, drug screening and toxicity evaluations. More specifically, the present invention relates to novel systems and methods used for production and control of 3-D architecture and morphology of living tissues and organs produced by mammalian cells using 3D porous scaffolds based on nano-cellulose. The resultant nano-cellulose based structures are useful as tools in high throughput assays for drugs. More particularly, embodiments of the present invention relate to systems and methods for evaluating a drug that comprise a microtiter plate comprising a plurality of wells, each well comprising: a 3D non-biodegradable, inert, nano-cellulose scaffold; and optionally cells capable of forming living tissue or organs; and optionally a drug having a biological activity of interest; and optionally a detector capable of detecting the biological activity in a high throughput format.

This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.

A method of pharmaceutically managing snoring and impaired breathing is provided. This invention relates to treating snoring, sleep apnea, and other forms of sleep-disordered breathing in those with or without symptoms of or the diagnosis of gastro-intestinal reflux disease (GERD). It comprises administration of a therapeutically effective dose of Prevacid (Lansoprazole) or any other medication that can be used to treat symptoms of hyper-acidity or gastrointestinal reflux disease (GERD). The therapeutic medication may be used alone or in combination with other pharmacologic agents or mechanical modalities including but not limited to decongestants, antihistamines or mechanical nasal toilet. It also is of benefit in improving breathing disorders that are present while awake.

The invention relates to cortex phellodendri polysaccharide extract and a preparation method and medical application thereof. The content of cortex phellodendri polysaccharide in the extract is counted by glucose, and the content of the polysaccharide accounts for above 65% of the cortex phellodendri extract in percentage by weight. Found by a large number of pharmacological experiments, the cortex phellodendri general polysaccharide extract has notable immunosuppressive activity, can be prepared into immunosuppressive medicaments or used as a medicinal material for preparing other immunosuppressive medicaments, and can be used for treating various immunoreaction-related diseases, including nephritis, pharyngitis, pneumonitis, upper respiratory tract infection, hepatitis, enteritis, gynecologic inflammation, rheumatoid arthritis, diabetes and other immune-related diseases.

The invention discloses a drug composition for resisting inflammation and easing pain and a preparation method and application thereof. The drug composition is prepared from aconitum sinomontanum nakai and geranium wilfordii maxim as bulk drugs by the unique extraction processes of the invention. The drug composition of the invention has the following advantages: 1, the novel TCM (traditional Chinese medicine) compound for resisting inflammation and easing pain provided by the invention meets the clinical requirements; 2, according to the pharmacological research on the mutual effect and compatible formula of aconitum sinomontanum nakai and geranium wilfordii maxim, the drug composition of the invention can significantly increase the pain threshold of mice compared with single aconitum sinomontanum nakai or geranium wilfordii maxim; 3, the drug composition of the invention has obvious effects of resisting inflammation, easing pain and enhancing human immunity, thus ensuring the wide application prospect; and 4, the drug composition of the invention can be prepared into any preparation by directly feeding the bulk drug of aconitum sinomontanum nakai and geranium wilfordii maxim or by processing the extracts of aconitum sinomontanum nakai and geranium wilfordii maxim, thus meeting the requirements of mass-production.

The invention discloses an ephedra total polysaccharide extractive and a preparation method and a medical application thereof. The ephedra total polysaccharide in the invention is acid total polysaccharide, calculated by glucose, and the weight percent content of the acid total polysaccharide accounts for 45% or over 45% of the total weight of ephedra total polysaccharide extractive. In the invention, a large number of pharmacological experiments discover that the ephedra acid total polysaccharide extractive has prominent immunosuppressive activity, has no toxic and side effects, can be prepared to drugs used as immunosuppressant or can be used as bulk drug for preparing other immunosuppressive drugs, and can be used for curing various diseases related to over-immunity, comprising allergic asthma, chronic nephritis, rheumatoid arthritis, systemic lupus erythematosus, body rejection caused by organ transplantation and other diseases related to over-immunity.

The present invention discloses an application of indole-2.3-diketone (MW147) in preparation of medicine for preventing and / or curing angiocardiopathy and cerebrovascular disease. Said MW147 has the action of preventing formation of AS and promoting repercussion of AS, so that it can be made into the medicine for resisting As.

The invention discloses applications of dendrobium nobile lindl alkaloids (DNLA) in medicines prepared for treating senile dementia and a product thereof. The DNLA is lipophilic total alkaloids composition which is extracted from the dendrobium nobile lindl. Compared with the prior art, the invention makes clear the pharmacological action and mechanism action of the DNLA for treating senile dementia by studying the action of the DNLA for protecting nerve cells and cerebral ischemia model and the influence of the DNLA on the capacity of learning and memory of rats, and provides pharmacological basis for the development and applications of the dendrobium nobile lindl medical material.

The invention belongs to the field of medicaments and provides an application of natural plant lobedfruit schizocapsarhizome and total saponin extract of the lobedfruit schizocapsarhizome, wherein the natural plant extract is total saponins of the lobedfruit schizocapsarhizome (the Latin name is Schizocapsa plantaginea Hance). The invention provides an extract technology of the total saponin extract of the lobedfruit schizocapsarhizome and the application of the total saponin extract of the lobedfruit schizocapsarhizome in treatment of liver cancer and nasopharyngeal carcinoma. The extract has strong antineoplastic activity and certain targeting property. Serum pharmacology tests prove that the extract still has strong pharmaceutical activity after be absorbed and metabolized, and the saponin extract can inhibit the expression of tumor cells VEGF and CD34 so as to inhibit the growth of capillaries of a tumor tissue and then inhibit the growth of a tumor. A plant source of the extract is a unique plant species, which has great development and utilization value, is planted in a certain scale and is cheap and easily obtained, in Guangxi province. The invention provides an antitumor extract with a wide prospect, so that a novel medicament for treating tumors is provided.

The present invention provides improved devices for biopsy, aspiration, stem cell acquisition, and methods of using the same. The devices balance aspiration with concurrent infusion to manage changes in pressure at the site of biopsy. The present invention can be adapted for any biopsy, aspiration, or cell harvest procedure, including adipose tissue aspiration and bone marrow aspiration (BMA). In particular, the present invention limits patient pain, prevents blood contamination, and increases cell mobilization, such as improved stem cell yields with intraosseous (10) pharmacological mobilization of stem cells during a BMA procedure, and with improved stem cell yields using pharmacological mobilization of stem cells from fat. The pharmacological mobilization of cells allows the harvest of cells from a biopsy many fold larger than existing methods.

Use of hyaluronic acid derivatives for the preparation of biomaterials for the prevention of the formation and the treatment of cutaneous scars, wherein the hyaluronic acid derivatives are optionally combined with pharmacologically or biologically active compounds.

The invention discloses application of a composition of artemisinin or a derivative thereof and an EGFR-TKI targeted drug in preparation of drugs for treating tumors of the head and neck. Experimentsprove that the artemisinin and the derivative (such as dihydroartemisinin) thereof can reverse drug resistance of the tumors of the head and neck to the targeted drug, and when the artemisinin and thederivative thereof are combined to the target drug to treat the tumors of the head and neck, a remarkable synergistic effect is achieved. Through experiments, it proves that the artemisinin and the derivative such as dihydroartemisinin thereof can inhibit protein phosphorylation such as STAT3, paxillin and FAK, by the activity, the effect of resisting the tumors of the head and neck of the targeted drug (such as osimertinib as an EGFR inhibitor) is enhanced, and pharmacological basis is provided for developing new application of artemisinins drugs.

The invention discloses an application of globeflower flavonoids in preparation of a medicine for treating itch dermatoses. The application range of globeflower flavonoids is expanded; a novel medicine is provided for treatment of itch dermatoses; from a pharmacology experiment, the globeflower flavonoids have good prevention and treatment effects on a mice chronic eczema model, have an obvious inhibiting effect on mice delayed-type allergic reaction caused by 2,4-dinitrofluorobenzene, have obvious anti-inflammatory effect in ear swelling in mice caused by xylene, and have a significant inhibiting effect on capillary permeability increase in mice caused by glacial acetic acid; and the globeflower flavonoids can have relatively good counteraction on guinea pig pruritus caused by histamine phosphate, are low in toxicity and safe to use, and have a relatively good application prospect.

The present invention relates generally to the fields of molecular biology and pharmacology. More particularly, it concerns the use of abscissic acid to treat various diseases, including neurodegenerative diseases and neuromuscular diseases.

A method for producing bronchorelaxation in a human or an animal affected by airway obstruction comprises administration of a pharmacologically effective amount of elemental iodine on activated charcoal (iodinated activated charcoal) to the intestine of said human or animal. A pharmaceutical composition comprising elemental iodine on activated charcoal and uses thereof is also disclosed.